Cargando…

Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma

The distribution of Endometrial Cancer (EC)-related deaths is uneven among the morphologic subtypes of EC. Serous Cancer (SC) makes 10% of all EC and accounts for 40% of EC-related deaths. We investigated expression of selected genes involved in epigenetic pathways by immunohistochemistry in a cohor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saglam, Ozlen, Cao, Biwei, Wang, Xuefeng, Toruner, Gokce A., Conejo-Garcia, Jose R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884513/ https://www.ncbi.nlm.nih.gov/pubmed/35226658 http://dx.doi.org/10.1371/journal.pone.0264014

Ejemplares similares

Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study
por: Paleari, Laura, et al.
Publicado: (2020)

Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer
por: Tagliaferri, Barbara, et al.
Publicado: (2020)

KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma
por: Saglam, Ozlen, et al.
Publicado: (2020)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
por: Torrisi, R, et al.
Publicado: (2008)

S100A9 expressed in ER(−)PgR(−) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival
por: Bergenfelz, Caroline, et al.
Publicado: (2015)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Study of Estrogen Receptor and Progesterone Receptor Expression in Breast Ductal Carcinoma In Situ by Immunohistochemical Staining in ER/PgR-Negative Invasive Breast Cancer
por: Dobrescu, Andrei, et al.
Publicado: (2011)

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
por: Torrisi, R, et al.
Publicado: (2007)

Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
por: Nishimura, Reiki, et al.
Publicado: (2011)

Association of the PROGINS PgR polymorphism with susceptibility to female reproductive cancer: A meta-analysis of 30 studies
por: Zhou, Chen, et al.
Publicado: (2022)

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index
por: Kurozumi, Sasagu, et al.
Publicado: (2017)

Association of +331G/A PgR Polymorphism with Susceptibility to Female Reproductive Cancer: Evidence from a Meta-Analysis
por: Chaudhary, Sanjib, et al.
Publicado: (2013)

Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology
por: Kurbel, Sven, et al.
Publicado: (2017)

SOX4 facilitates PGR protein stability and FOXO1 expression conducive for human endometrial decidualization
por: Huang, Pinxiu, et al.
Publicado: (2022)

MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway
por: Li, Yue, et al.
Publicado: (2018)

Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review
por: Yokoyama, Takanori, et al.
Publicado: (2018)

Primary constitutional MLH1 epimutations: a focal epigenetic event
por: Dámaso, Estela, et al.
Publicado: (2018)

The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability
por: Russell, Holly, et al.
Publicado: (2020)

ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab
por: Kurozumi, Sasagu, et al.
Publicado: (2015)

Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas
por: Sorbye, Sveinung W, et al.
Publicado: (2013)

Correction to: The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability
por: Russell, Holly, et al.
Publicado: (2021)

Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
por: Gallitto, Matthew, et al.
Publicado: (2020)

Identification of a Novel Mutation Exacerbated the PSI Photoinhibition in pgr5/pgrl1 Mutants; Caution for Overestimation of the Phenotypes in Arabidopsis pgr5-1 Mutant
por: Wada, Shinya, et al.
Publicado: (2021)

Isolated MLH1 Loss by Immunohistochemistry Because of Benign Germline MLH1 Polymorphisms
por: Bosch, Dustin E., et al.
Publicado: (2022)

MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas
por: Kaneko, Enami, et al.
Publicado: (2021)

PGRL2 triggers degradation of PGR5 in the absence of PGRL1
por: Rühle, Thilo, et al.
Publicado: (2021)

Lynch Syndrome Associated with Two MLH1 Promoter Variants and Allelic Imbalance of MLH1 Expression
por: Hesson, Luke B, et al.
Publicado: (2015)

Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation
por: Pinto, Diana, et al.
Publicado: (2018)

Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer
por: Loukovaara, Mikko, et al.
Publicado: (2021)

Testing for Lynch Syndrome in Endometrial Carcinoma: From Universal to Age-Selective MLH1 Methylation Analysis
por: Pasanen, Annukka, et al.
Publicado: (2022)

MLH1 Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening—A Critical Appraisal
por: Plotkin, Anna, et al.
Publicado: (2023)

Compendio informativo PGR : órgano de difusión de la Procuraduría General de la República.
Publicado: (1995)

MSH2 and MLH1 testing
por: Kurzawski, Grzegorz, et al.
Publicado: (2008)

Clinical Significance of Epigenetic Inactivation of hMLH1 and BRCA1 in Tunisian Patients with Invasive Breast Carcinoma
por: Karray-Chouayekh, Sondes, et al.
Publicado: (2009)

Assessing pathogenicity of MLH1 variants by co-expression of human MLH1 and PMS2 genes in yeast
por: Vogelsang, Matjaz, et al.
Publicado: (2009)

Nuclear Progestin Receptor (Pgr) Knockouts in Zebrafish Demonstrate Role for Pgr in Ovulation but Not in Rapid Non-Genomic Steroid Mediated Meiosis Resumption
por: Zhu, Yong, et al.
Publicado: (2015)

MUS81 Generates a Subset of MLH1-MLH3–Independent Crossovers in Mammalian Meiosis
por: Holloway, J. Kim, et al.
Publicado: (2008)

Human MutLγ, the MLH1–MLH3 heterodimer, is an endonuclease that promotes DNA expansion
por: Kadyrova, Lyudmila Y., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g1cmcetqtddh75hfups67c3481